Fierce Pharma

FEBRUARY 9, 2023

Now, it plans 15 drug launches by 2030 aliu Thu, 02/09/2023 - 10:00 AstraZeneca met CEO Pascal Soriot's $40B revenue goal early.

245

245

European Pharmaceutical Review

MARCH 28, 2024

billion by 2030. percent between 2024-2030. by 2030 appeared first on European Pharmaceutical Review. The global pharmaceutical and biotechnology environmental monitoring market valued $24 billion in 2023, according to a report by Verified Market Research. This figure is projected to increase to $38.1 PerkinElmer, Inc.

Marketing 81

Marketing Pharmaceutical Pharma Management 81

Fierce Pharma

OCTOBER 2, 2023

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

Leads 173

Leads Sales Pharma 173

European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. percent between 2023 and 2030. percent from 2023 to 2030. The post HPLC market projected to value $8 million by 2030 appeared first on European Pharmaceutical Review. What is driving the HPLC market?

Marketing 81

Marketing Biopharma Pharmaceutical Pharma 81

European Pharmaceutical Review

JULY 18, 2023

billion by 2030. Digitalisation to boost quality management systems market The post QMS market to value nearly $4b by 2030 appeared first on European Pharmaceutical Review. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Marketing 94

Marketing Manufacturing Management Pharmaceutical manufacturing 94

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. billion by 2030 appeared first on European Pharmaceutical Review. According to a market report , the global RNA therapy clinical trials market is anticipated to reach $3.5

Marketing 90

Marketing Safety Pharmaceutical Medicine 90

MedCity News

FEBRUARY 17, 2023

For example, one said that healthcare will be close to establishing a value-based formulary by 2030, and another said that longitudinal patient tracking will become a more important part the drug pricing process. Panelists at a recent pharmacy conference were optimistic about the future of value-based drug contracting.

Healthcare 114

Healthcare Healthcare Patients Pharma 114

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Manufacturing 93

Manufacturing Pharma Pharmaceutical Marketing 93

Fierce Pharma

FEBRUARY 29, 2024

The company aims to have at least eight blockbuster cancer drugs by 2030, with a focus on four main cancer types.

70

70

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review. The global buccal drug delivery market is projected to grow from $3.38

Marketing 52

Marketing Management Patients Pharmaceutical 52

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Sales 86

Sales Pharma Government Medicine 86

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Manufacturing 84

Manufacturing Marketing Side effects Transportation 84

Fierce Pharma

JUNE 12, 2023

Bayer recently laid out its ambition | Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.

Sales goal 345

Sales goal Sales 345

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Marketing 74

Marketing Pharmaceutical Manufacturing Pharma 74

Fierce Pharma

FEBRUARY 7, 2024

Overall, the company is pushing to generate 30% of its revenues from oncology by 2030. In 2023, the number was 11%.

258

258

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

pharmaphorum

APRIL 16, 2024

Boehringer Ingelheim says the strongest R&D pipeline in its history is set to deliver 25 new product launches between now and 2030

114

114

Pharmaceutical Technology

JUNE 14, 2023

The recommendations to combat AMR propose that there should be a 20% reduction in the total human consumption of antibiotics by 2030 alongside an even larger pushback against their use in animals, per the 13 June announcement.

Sales 52

Sales Pharmaceutical 52

Medico Reach

SEPTEMBER 12, 2022

billion by 2030. Gastrointestinal Endoscopic Devices Market Growth (2022-2030) appeared first on MedicoReach. The demand for this procedure contributes significantly to the gastrointestinal endoscopic market size was valued at USD 12.6 billion in 2021. The market is further expected to grow at a rate of 9.4% The post U.S.

Marketing 52

Marketing Doctors Training Medical 52

pharmaphorum

DECEMBER 7, 2023

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

Sales 82

Sales 82

Pharmaceutical Commerce

APRIL 17, 2024

A panel uncovers the value in meeting carbon-neutral goals by 2030.

105

105

PharmaVoice

FEBRUARY 20, 2024

By 2030, the AI market is expected to reach $187.95 A significant growth is predicted for both AI and IoT in healthcare. billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

Healthcare 104

Healthcare Healthcare Marketing 104

Fierce Pharma

AUGUST 4, 2023

The company is sticking to its ambitions of pulling a third of its revenue from its oncology portfolio by 2030. For years, Gilead has been on a mission to become a power player in oncology. | This year, the company expects $3 billion to come from its cancer trio of Trodelvy, Tecartus and Yescarta.

130

130

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. percent between 2022-2030. Based on the research by Roots Analysis, it is expected to hold 37 percent of the market share by 2030.

Manufacturing 52

Manufacturing Pharmaceutical Marketing 52

Pharmaceutical Technology

SEPTEMBER 15, 2023

A new report found that the Remote Patient Monitoring (RPM) sector will grow, since the pandemic revealed the benefits of remote healthcare.

Patients 52

Patients Marketing Healthcare Healthcare 52

PharmExec

JANUARY 15, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Manufacturing 52

Manufacturing Marketing Pharmaceutical 52

Pharmaceutical Commerce

JANUARY 15, 2024

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

Manufacturing 52

Manufacturing Marketing Pharmaceutical 52

European Pharmaceutical Review

FEBRUARY 2, 2024

Facilitated by more than 3,000m² of floor space at the site, Orano Med shared that it is aiming to produce ten times this quantity by the end of the 2030. The build of ATLab Valenciennes has been selected under the France 2030 plan. As a result, the project will receive public support of almost €3.8

Manufacturing 86

Manufacturing Distribution Leads Pharmaceutical 86

Pharmaceutical Technology

SEPTEMBER 6, 2023

AstraZeneca is working with its collaborators to ensure the changes are not just internal but across the entire chain footprint.

52

52

Pharmaceutical Technology

MARCH 27, 2024

The market for multiple sclerosis therapies is expected to be worth over $41bn by 2030, according to GlobalData.

Marketing 52

Marketing 52

Pharmaceutical Technology

MARCH 25, 2024

An unnamed Chinese partner takes on AR1001 in an APAC Alzheimer’s market predicted to be worth $2.6bn by 2030

Marketing 52

Marketing 52

Pharmaceutical Commerce

OCTOBER 17, 2023

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

Marketing 52

Marketing 52

Pharmaceutical Commerce

OCTOBER 11, 2023

The report also references a CAGR of 7.8% through that year.

Manufacturing 52

Manufacturing Marketing Pharma 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. With the personalised medicine market reaching $93bn by 2030, there will be a range of treatments available. It is the year 2030. If a vaccine is not yet available, and the cancer has begun to grow, personalised medicine will be your best therapeutic solution.

Healthcare 137

Healthcare Healthcare Electronics Healthcare Provider 137

Pharmaceutical Commerce

OCTOBER 20, 2023

Sector is anticipated to grow at a CAGR of 9.3%.

Marketing 52

Marketing 52

PharmExec

JUNE 1, 2023

Bloomberg Intelligence survey credits increased medication access for potential spike.

Sales 52

Sales Medical 52

PharmExec

NOVEMBER 15, 2023

The global cost of clinical research and trials is estimated to exceed $85 billion by 2030, which provides an opportunity for artificial intelligence to streamline processes.

Pharma 52

Pharma 52